News and Announcements
SUDA LTD Announces Feasibility Agreement with Pfizer
- Published March 29, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
SUDA LTD (ASX: SUD), leaders in the oro-mucosal drug delivery, announced that it has entered into a feasibility agreement with Pfizer consumer Healthcare.
KEY TAKEAWAYS:
- Under the agreed work plan, SUDA will apply its proprietary OroMist® oro-mucosal spray technology to two over-the-counter (OTC) molecules for evaluation by Pfizer.
Mr Stephan Carter, SUDA’S CEO and Managing Director, commented: “We are delighted to be working with Pfizer to assess the feasibility of two interesting drugs with our OroMist® platform, where we believe that our technology can offer a unique advantage.”
SUDA Ltd is a drug delivery company headquartered in Perth, WA. The Company is developing low-risk oral sprays using novel formulations of existing pharmaceuticals. The many potential benefits of administering drugs through the cheeks, tongue, gums to include ease of use, lower dosage, reduced side effects and faster response time.